News by Subject
News by Disease
News by Date
Post Your News
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
US & Canada
Post an Event
News | News By Subject | News by Disease |
News By Date | Search News
12/18/2013 1:48:03 PM
LONDON, UK, 18 December, 2013 - Skyepharma PLC (LSE SKP), the expert oral and inhalation drug delivery company, today announces that it has served a renewal notice on Aenova France SAS (“Aenova”) to extend the lease of its manufacturing business and premises in Lyon (together “the Facility”) to Aenova until 30 June 2016 at a rental of €2 million (£1.7 million at current rates) per annum. This follows the outcome of an independent expert determination process in Skyepharma’s favour.
During the remaining period of the lease, Aenova is obliged to manage and be responsible for the financial performance of the Facility on a day-to-day basis. Skyepharma’s existing contractual arrangements with its own partners are unaffected and during the remaining period of the lease Aenova will continue to manufacture and supply the Skyepharma products currently produced at the Facility.
Unless both parties agree otherwise, the lease will normally expire on 30 June 2016 and, subject to obtaining appropriate consents and consultations, the Facility would revert to Skyepharma following termination of the lease. In anticipation of this, and with Aenova’s agreement, Skyepharma has initiated a process to identify whether any third party would be interested in making use of surplus capacity at the Facility.
For further information please contact:
Peter Grant, Chief Executive Officer +44 207 881 0524
Andrew Derodra, Chief Financial Officer
Julia Phillips/Stephanie Cuthbert/Natalie Garland-Collins +44 207 269 7121
Shaun Dobson/Jennifer Wyllie +44 207 496 3000
Skyepharma combines proven scientific expertise with validated proprietary drug delivery technologies to develop innovative oral and inhalation pharmaceutical products. The Group is eligible for revenues from 14 approved products in the areas of inhalation, oral, topical and injectable drug delivery as well as generating income from the development of further products and technology licenses. The products developed by the Group are marketed throughout the world by big pharma as well as speciality pharmaceutical companies. For more information, visit www.skyepharma.com
About the Lyon Manufacturing Facility
Skyepharma’s manufacturing facility in Saint Quentin-Fallavier, near Lyon, France, is leased to the Aenova Group which manages the Facility on a day to day basis. The Facility manufactures six products which use the Geomatrix™ family of technologies and one other oral product based on Skyepharma’s solubilisation technology. The Facility has current good manufacturing (“cGMP”) status, with approvals, amongst others, to supply to both Europe and the United States. The facility has recently been inspected by the FDA, and no inspectional observations were raised.
Help employers find you! Check out all the jobs and post your resume.